# Adaptive Biotechnologies Price Target Lifted to $28.94 as Analysts Maintain Buy Consensus

- URL: https://stocks.freetheai.org/news/adaptive-biotechnologies-price-target-lifted-to-28-94-as-analysts-maintain-buy-10c1e5
- Published: 2026-10-12T16:20:03Z
- Category: analyst_ratings; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:ADPT](https://stocks.freetheai.org/symbols/NASDAQ-ADPT)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Wall Street analysts covering Adaptive Biotechnologies Corporation (ADPT) have increased their average 12-month price target on the stock to $28.94, up from a previous figure of $28.31. Individual target estimates span between $21 and $35 per share. Based on the October 9 closing price, the revised average projection suggests a potential gain of around 9%. Meanwhile, shares traded at $25.42, falling 4.04% during today's session.

The target adjustment reflects continued optimism among market watchers. Out of nine analysts covering the biopharmaceutical company, eight recommend buying the stock and one advises holding, with no sell recommendations. The unanimous lack of negative ratings highlights solid confidence in the business's outlook despite near-term market fluctuations.

Investors will look for future corporate updates and financial reporting to see whether the company can meet expectations and close the gap toward the $28.94 target. Key factors to track include performance relative to the lower $21 and upper $35 estimate bounds, as well as any shifts in analyst recommendations over coming quarters.

## Key points

- Analysts raised the average 12-month price target for Adaptive Biotechnologies to $28.94 from $28.31.
- Price target forecasts among eight analysts range from $21 to $35 per share.
- The updated average target implies roughly 9% potential upside from the October 9 closing price.
- The overall consensus rating remains Buy, with eight Buy ratings, one Hold, and zero Sells from nine analysts.
- Shares of Adaptive Biotechnologies Corp. were trading at $25.42, down 4.04% on the day.

## Questions and answers

### What is the updated price target for Adaptive Biotechnologies stock?

The average 12-month price target for Adaptive Biotechnologies has been raised to $28.94, up from $28.31, with analyst forecasts ranging from $21 to $35 per share.

### What is the consensus rating for Adaptive Biotechnologies stock?

The consensus rating remains Buy across nine analysts, consisting of eight Buy ratings, one Hold, and zero Sell recommendations.

### How much upside does the new price target imply for Adaptive Biotechnologies?

The updated average price target of $28.94 implies approximately 9% upside based on the October 9 closing price.